Published in Med Pediatr Oncol on January 01, 1985
National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst (2001) 5.09
Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA (1998) 5.09
Two members of the Tcf family implicated in Wnt/beta-catenin signaling during embryogenesis in the mouse. Mol Cell Biol (1998) 3.09
Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology (1999) 3.06
The role of DNA mismatch repair in platinum drug resistance. Cancer Res (1996) 2.88
A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res (1999) 2.50
The role of DNA mismatch repair in drug resistance. Clin Cancer Res (1998) 2.49
Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells (1990) 2.43
Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res (1996) 2.37
Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol (1999) 2.29
Tumor chemosensitivity and chemoresistance assays. Cancer (1996) 2.14
Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer (1993) 2.10
Increased volume and decreased emptying of the gallbladder in large (morbidly obese, tall normal, and muscular normal) people. Gastroenterology (1990) 2.10
Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene (1994) 1.88
Fatigue patterns observed in patients receiving chemotherapy and radiotherapy. Cancer Invest (2000) 1.86
Characterization of cisplatin-resistant COLO 316 human ovarian carcinoma cells. Eur J Cancer Clin Oncol (1989) 1.68
Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol (2001) 1.61
Temperament related to early-onset substance use: test of a developmental model. Prev Sci (2001) 1.60
Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance. J Natl Cancer Inst (1997) 1.58
Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity. Gynecol Oncol (1996) 1.57
cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res (1988) 1.56
Synbiotic consumption changes the metabolism and composition of the gut microbiota in older people and modifies inflammatory processes: a randomised, double-blind, placebo-controlled crossover study. Aliment Pharmacol Ther (2013) 1.54
Profiles of women age 30-39 and age less than 30 with epithelial ovarian cancer. Obstet Gynecol (1993) 1.52
In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res (1997) 1.50
Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin Cancer Res (1997) 1.47
In vitro polymerization of tau protein monitored by laser light scattering: method and application to the study of FTDP-17 mutants. Biochemistry (2000) 1.46
Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med (1982) 1.46
Peritoneal cytology as an indicator of disease in patients with residual ovarian carcinoma. Obstet Gynecol (1988) 1.45
Circulating immunoglobulin complexes in Wegener's granulomatosis. Am J Med (1976) 1.43
Normal fasting volume and postprandial emptying of the denervated donor gallbladder in liver transplant recipients. Gastroenterology (1994) 1.41
Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol Cell Biol (1992) 1.39
Hydrodynamic compression of the right atrium: a new echocardiographic sign of cardiac tamponade. Circulation (1983) 1.37
Exercise reduces daily fatigue in women with breast cancer receiving chemotherapy. Med Sci Sports Exerc (2001) 1.37
Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion. Cancer Res (1985) 1.30
Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatin. Cancer Res (1997) 1.29
Identification of genes that mediate sensitivity to cisplatin. Mol Pharmacol (2001) 1.28
Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma. Cancer Commun (1990) 1.27
Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer (2001) 1.26
Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br J Cancer (1994) 1.26
Vancomycin-induced vasculitis. South Med J (1986) 1.24
Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Saf (2001) 1.24
Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection. Cancer Res (1983) 1.23
Primary ovarian cancer chemotherapy: current standards of care. Br J Cancer (2003) 1.23
Rapid superselective high-dose cisplatin infusion for advanced head and neck malignancies. Head Neck (1992) 1.22
Targeted chemoradiation for advanced head and neck cancer: analysis of 213 patients. Head Neck (2000) 1.21
Myxoid leiomyosarcoma of the uterus. A report of six cases. Am J Surg Pathol (1982) 1.20
Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study. J Clin Oncol (1995) 1.18
Anti-peptide antibodies detect oncogene-related proteins in urine. Proc Natl Acad Sci U S A (1985) 1.18
Modulation of cis-diamminedichloroplatinum(II) accumulation and sensitivity by forskolin and 3-isobutyl-1-methylxanthine in sensitive and resistant human ovarian carcinoma cells. Int J Cancer (1991) 1.18
Three-dimensional reconstruction of ventricular septal defects: validation studies and in vivo feasibility. J Am Coll Cardiol (1994) 1.17
Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy. J Clin Oncol (1987) 1.17
Extended CSF cytarabine exposure following intrathecal administration of DTC 101. J Clin Oncol (1993) 1.16
Phase I/pharmacokinetic study of intraperitoneal cisplatin and etoposide. Cancer Res (1987) 1.16
Closure of patent foramen ovale for paradoxical emboli: intermediate-term risk of recurrent neurological events following transcatheter device placement. J Am Coll Cardiol (2000) 1.15
Totally implantable system for peritoneal access. J Clin Oncol (1984) 1.15
Enhanced expression and activity of DNA polymerase beta in human ovarian tumor cells: impact on sensitivity towards antitumor agents. Oncogene (2001) 1.15
Interventricular septal configuration as a predictor of right ventricular systolic hypertension in children: a cross-sectional echocardiographic study. Circulation (1983) 1.14
Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol (1987) 1.13
Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy. Clin Cancer Res (2000) 1.13
Relationship between % heart rate reserve and % VO2 reserve in treadmill exercise. Med Sci Sports Exerc (1998) 1.13
New perspectives in the assessment of cardiac chamber dimensions during development and adulthood. J Am Coll Cardiol (1992) 1.13
Echocardiographic measurement of right ventricular volume. Circulation (1984) 1.11
Respiratory enzymes and mitochondrial morphology of HeLa and L cells treated with chloramphenicol and ethidium bromide. J Cell Biol (1972) 1.11
Phase I study of highly selective supradose cisplatin infusions for advanced head and neck cancer. J Clin Oncol (1994) 1.11
Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. J Clin Oncol (1992) 1.11
Role of metallothionein in carcinogenesis. Toxicol Appl Pharmacol (1994) 1.10
Increased sensitivity to cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells in response to treatment with 12-O-tetradecanoylphorbol 13-acetate. J Biol Chem (1990) 1.10
A comparison of the Pipelle device and the Vabra aspirator as measured by endometrial denudation in hysterectomy specimens: the Pipelle device samples significantly less of the endometrial surface than the Vabra aspirator. Am J Obstet Gynecol (1993) 1.09
Molecular modeling of the intrastrand guanine-guanine DNA adducts produced by cisplatin and oxaliplatin. Mol Pharmacol (1999) 1.08
The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma. Gynecol Oncol (1999) 1.07
Prevalence of aortic valve prolapse with bicuspid aortic valve and its relation to aortic regurgitation: a cross-sectional echocardiographic study. Am J Cardiol (1984) 1.07
Defects in cell-mediated immunity during growth of a syngeneic simian virus-induced tumor. Int J Cancer (1975) 1.07
An integrated mechanism for systolic anterior motion of the mitral valve in hypertrophic cardiomyopathy based on echocardiographic observations. Am Heart J (1987) 1.07
Functional scaffold-free 3-D cardiac microtissues: a novel model for the investigation of heart cells. Am J Physiol Heart Circ Physiol (2012) 1.07
Oxidative regulation of fatty acid-induced tau polymerization. Biochemistry (2000) 1.07
Cisplatin and taxol activate different signal pathways regulating cellular injury-induced expression of GADD153. Br J Cancer (1996) 1.06
Immunoturbidimetric assays of apolipoproteins A, AI, AII, and B in serum. Clin Chem (1986) 1.05
Biochemical characterization of the human arsenite-stimulated ATPase (hASNA-I). J Biol Chem (1998) 1.03
Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin. J Clin Invest (1990) 1.03
Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells. Br J Cancer (1999) 1.03
A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. J Clin Oncol (1994) 1.02
High expression of the HMG box factor sox-13 in arterial walls during embryonic development. Nucleic Acids Res (1998) 1.02
Three-dimensional echocardiography. In vivo validation for right ventricular volume and function. Circulation (1994) 1.01
Short-term cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Chemother Pharmacol (1990) 1.01
The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair-deficient tumour cells. Br J Cancer (1998) 1.00
Improved targeting of platinum chemotherapeutics. the antitumour activity of the HPMA copolymer platinum agent AP5280 in murine tumour models. Eur J Cancer (2004) 1.00
Comparative study of ozone (O3) uptake in three strains of rats and in the guinea pig. Toxicol Appl Pharmacol (1988) 0.99
Congenital aneurysms of the left atrium: recognition by cross-sectional echocardiography. Circulation (1982) 0.99
Cell interactions in adoptive immune rejection of a syngeneic tumor. Int J Cancer (1974) 0.99
Left atrial dimensions in growth and development: normal limits for two-dimensional echocardiography. J Am Coll Cardiol (1990) 0.99
Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells. Cancer Res (1993) 0.98
Hypoxia-induced enrichment and mutagenesis of cells that have lost DNA mismatch repair. Cancer Res (2001) 0.98
Induction of the growth arrest and DNA damage-inducible gene GADD153 by cisplatin in vitro and in vivo. Br J Cancer (1994) 0.98
Enhanced potentiation of cisplatin cytotoxicity in human ovarian carcinoma cells by prolonged glutathione depletion. Chem Biol Interact (1988) 0.97
Antiemetic efficacy of dexamethasone. Randomized, double-blind, crossover study with prochlorperazine in patients receiving cancer chemotherapy. N Engl J Med (1984) 0.97
Yeast mutants as a model system for identification of determinants of chemosensitivity. Pharmacol Rev (2000) 0.97
P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin. Cancer Res (2001) 0.97